A recent study showed that, compared with healthy donors, MS patients had lower resting CD4+ CD25+ CD45RA+ CCR7+ Tregs and more activated CD4+ CD25hi CD45RA- Foxp3hi Tregs even before treatment (40). Here, CD4 is linked to myeloid sarcoma.